Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Mitochondrial protease oma1 as a marker for breast cancer

a technology of mitochondrial protease and breast cancer, which is applied in the field of mitochondrial protease oma1 as a theranostic marker, can solve the problems of breast cancer-related deaths, mitochondrial dysfunction, and metastatic tumors of vital organs,

Pending Publication Date: 2021-07-08
NUTECH VENTURES
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patent is about using a protein called OMA1 to diagnose and monitor treatment effectiveness in breast cancer. The researchers found that when OMA1 is reduced in expression, it indicates metastatic breast cancer. Additionally, they found that measuring the expression level of OMA1 before and after treatment can show if the therapy is effective. This new biomarker could help improve the diagnosis and treatment of breast cancer.

Problems solved by technology

Metastasis to vital organs including lungs, liver, bone, and brain is a major cause for breast cancer-related deaths.
Perturbations to mitochondrial integrity by mutations or functional decline lead to mitochondrial dysfunction, potentially impacting metastatic properties of neoplastic cells.
However, the mechanisms by which mitochondrial malfunction contributes to cancer progression remain far from clear.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Mitochondrial protease oma1 as a marker for breast cancer
  • Mitochondrial protease oma1 as a marker for breast cancer
  • Mitochondrial protease oma1 as a marker for breast cancer

Examples

Experimental program
Comparison scheme
Effect test

example

[0040]In this Example, the role of the metallopeptidase OMA1 in regulation of tumor progression in breast cancer cells was analyzed.

Materials and Methods

[0041]Generation of Stable OMA1 Knockdown Cell Lines

[0042]21MT-1 cells were obtained from Dr. Hamid Band at the University of Nebraska Medical Center. This cell line was isolated from metastatic pleural effusion mammary tumor specimens. The 21MT-1 cells were cultured in α-MEM media supplemented with 5% fetal bovine serum (FBS), 1% Penicillin-Streptomycin (PS), 1% L-glutamine, 20 mM HEPES, non-essential amino acids, sodium pyruvate (all stated reagents from Invitrogen), 12.5 ng / ml epidermal growth factor (EGF) and 1 μg / ml hydrocortisone (both from Sigma-Aldrich). MCF10A (ATCC CRL-10317), human normal breast tissue cell line, were cultured in DMEM / F12 (Mediatech) and supplemented with 1% L-glutamine, 1% Penicillin-Streptomycin, 5% Horse Serum, 0.1 ng / ml cholera toxin, 0.5 μg / ml hydrocortisone, 10 μg / ml insulin, and 0.02 ng / μl rhEGF (a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
binding affinityaaaaaaaaaa
morphologyaaaaaaaaaa
Login to View More

Abstract

The use of mitochondrial protease OMA1 as a theranostic marker for breast cancer, tumor progression, metastatis and drug responsiveness is disclosed herein.

Description

CROSS REFERENCE TO RELATED APPLICATION[0001]This application is a continuation application of national phase application Ser. No. 16 / 476,961 (published as U.S. Publication No. 2019 / 0369100), filed on Jul. 10, 2017, which claims benefit of International Application No. PCT / US2018 / 013497 (published as WO 2018 / 132662), filed Jan. 12, 2018, which claims benefit to U.S. Provisional Patent Application No. 62 / 446,434, filed on Jan. 14, 2017, all of which are hereby incorporated by reference in its their entireties.BACKGROUND OF THE DISCLOSURE[0002]The present disclosure relates generally to the use of mitochondrial protease OMA1 as a theranostic marker for breast cancer, tumor progression, metastatis and drug responsiveness. Particularly, it has been found herein that impaired mitochondrial protein quality control (MQC) function through OMA1 deficit can drive malignancy and metastatic progression in breast cancer.[0003]Breast cancer is a complex disease affecting over 180,000 women annuall...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): G01N33/574C07K16/30C12N9/64
CPCG01N33/57415C07K16/3015G01N2333/8146G01N33/57484C12N9/6489G01N33/574G01N2800/52
Inventor KIDAMBI, SRIVATSANKHALIMONCHUK, OLEH
Owner NUTECH VENTURES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com